Does Axitinib Improve Outcomes in Favorable-Risk Patients With Metastatic Kidney Cancer?
Posted: Monday, February 4, 2019
The targeted therapy axitinib was found to have a measurable survival benefit in favorable-risk patients with metastatic renal cell carcinoma, according to research published in Targeted Oncology. FavorAx, a phase II study, determined the risk using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
“The encouraging [progression-free survival] and favorable safety profile observed in the FavorAx study support the administration of axitinib in patients with metastatic renal cell carcinoma with favorable IMDC risk and a history of prior sunitinib or pazopanib,” concluded Ilya Tsimafeyeu, MD, of the Kidney Cancer Research Bureau, Moscow, and colleagues.
A total of 21 patients were included in the study, all of whom received axitinib and had clear-cell metastatic renal cell carcinoma, favorable-risk disease, and prior treatment of first-line sunitinib (67%) or pazopanib (33%). The median progression-free survival from first-line therapy was 17 months. The mean participant age was 60 years, and 62% of enrollees were men.
At a median study follow-up of 25 months, the median progression-free survival was 19 months, with a median overall survival not reached. At 18 months, the median overall survival rate was 85.7%. Overall, one patient experienced a complete response. The objective response rate was 33%. A total of 11 patients had changes in axitinib dosage, with 7 undergoing dose escalation and 4 receiving a dose reduction.
In terms of toxicity, 19% of patients experienced grade 3 adverse events. No patient discontinued treatment due to toxicity.
Disclosure: The study authors reported no conflicts of interest.